Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Summary not available.
Oramed Pharmaceuticals (Nasdaq: ORMP) will host a webinar on March 30, 2022, at 12:00 p.m. ET, featuring experts discussing the need for oral insulin in type 2 diabetes. Presenters include Dr. Anne Peters from USC and Dr. Alexander Fleming, formerly with the FDA. They will address the treatment landscape and the potential of Oramed's oral insulin candidate, ORMD-0801, currently in Phase 3 trials. A live Q&A session will follow. For registration, visit here.
Oramed Pharmaceuticals (Nasdaq: ORMP) has successfully completed patient enrollment for its Phase 2 trial of the oral insulin capsule ORMD-0801, targeting non-alcoholic steatohepatitis (NASH) in Type 2 diabetes patients. NASH affects 4 to 17 million adults in the U.S., with no approved treatments currently available. The trial, conducted in the U.S. and Israel, will evaluate ORMD-0801's safety and efficacy after 12 weeks of dosing. The global NASH drug market is projected to reach $84 billion by 2029. Oramed anticipates reporting topline results that support previous efficacy findings.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) announced that CEO Nadav Kidron will present at the Barclays Global Healthcare Conference in Miami, Florida, from March 15-17, 2022. Kidron's presentation is scheduled for Tuesday, March 15, 2022, at 3:50 p.m. Eastern time. The event will be webcasted and available for view for 90 days. Oramed is a pioneer in oral drug delivery systems, particularly targeting diabetes treatment with its lead oral insulin candidate, ORMD-0801, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals (NASDAQ: ORMP) provided a shareholder update highlighting significant advancements in 2021. The company is advancing its oral insulin and COVID-19 vaccine candidates through pivotal trials, expecting topline results in H2 2022. ORMP has achieved over 75% enrollment in its Phase 3 oral insulin trial and is progressing with its oral COVID-19 vaccine in South Africa. With approximately $174 million in cash as of December 2021, Oramed is well-positioned for upcoming milestones, including key clinical results and potential emergency use authorization for its vaccine.
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) announced that the European Patent Office has granted it a patent for its oral protein delivery platform technology, supporting its lead drug candidate ORMD-0801, which is undergoing pivotal Phase 3 studies. This patent involves a novel method for purifying protease inhibitors, vital for protecting therapeutic proteins during digestion. With this patent, Oramed now holds 88 patents and 35 pending, enhancing its intellectual property position in the oral delivery market for therapeutics, specifically for diabetes treatment.
MyMD Pharmaceuticals has announced that its investment company, Oravax Medical, signed a Cooperation and Purchase Agreement with Vietnam's Tan Thanh Holdings for an initial pre-order of 10 million doses of an oral COVID-19 vaccine currently under development. The deal also allows for significant follow-on orders. Oravax's vaccine targets less mutable proteins and has benefits in logistics due to simplified storage requirements. MyMD holds a 13% stake in Oravax, along with a 2.5% royalty on future net sales. This agreement may boost revenue potential for both companies in the ASEAN region.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam's Tan Thanh Holdings. This agreement involves an initial pre-order of 10 million doses of an oral COVID-19 vaccine currently in development, with potential follow-on orders worth hundreds of millions. Tan Thanh will fund advanced clinical trials and regulatory approval, targeting the ASEAN market. Oravax's vaccine aims to combat COVID-19 variants and offers logistical advantages. The ASEAN pharmaceutical market is valued at $25 billion and is growing rapidly.
Oramed Pharmaceuticals announced the enrollment of the first participant in a Phase 1 clinical trial for its oral COVID-19 vaccine, developed by subsidiary Oravax Medical, in Johannesburg, South Africa. The trial aims to assess safety, tolerability, and efficacy while targeting three SARS-CoV-2 surface proteins, potentially increasing effectiveness against variants. The study will enroll 24 participants unvaccinated and without prior infection, with doses administered three weeks apart. Oramed anticipates rapid progress towards pivotal trials for emergency use approval, highlighting the vaccine's scalable manufacturing and distribution advantages.
Oramed Pharmaceuticals (Nasdaq: ORMP) has appointed Netanel Derovan as Chief Legal Officer and Company Secretary, effective January 9, 2022. Derovan, with over 20 years in senior legal roles, previously served at Teva Pharmaceutical Industries and Goldfarb Seligman. His expertise is expected to bolster Oramed's corporate strategy. CEO Nadav Kidron expressed confidence in Derovan's operational skills contributing to the company's growth, particularly as it approaches significant milestones.